- Home
- UPST vs NUVL Comparison
UPST vs NUVL Comparison
Compare UPST & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPST
- NUVL
- Stock Information
- Founded
- UPST 2012
- NUVL 2017
- Country
- UPST United States
- NUVL United States
- Employees
- UPST N/A
- NUVL N/A
- Industry
- UPST Finance: Consumer Services
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- UPST Finance
- NUVL Health Care
- Exchange
- UPST Nasdaq
- NUVL Nasdaq
- Market Cap
- UPST 6.6B
- NUVL 5.6B
- IPO Year
- UPST 2020
- NUVL 2021
- Fundamental
- Price
- UPST $46.00
- NUVL $68.00
- Analyst Decision
- UPST Buy
- NUVL Strong Buy
- Analyst Count
- UPST 14
- NUVL 10
- Target Price
- UPST $77.08
- NUVL $113.10
- AVG Volume (30 Days)
- UPST 4.7M
- NUVL 601.6K
- Earning Date
- UPST 05-06-2025
- NUVL 05-08-2025
- Dividend Yield
- UPST N/A
- NUVL N/A
- EPS Growth
- UPST N/A
- NUVL N/A
- EPS
- UPST N/A
- NUVL N/A
- Revenue
- UPST $676,961,000.00
- NUVL N/A
- Revenue This Year
- UPST $50.82
- NUVL N/A
- Revenue Next Year
- UPST $22.62
- NUVL N/A
- P/E Ratio
- UPST N/A
- NUVL N/A
- Revenue Growth
- UPST 23.43
- NUVL N/A
- 52 Week Low
- UPST $20.60
- NUVL $61.80
- 52 Week High
- UPST $96.43
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- UPST 36.09
- NUVL 31.43
- Support Level
- UPST $43.24
- NUVL $67.47
- Resistance Level
- UPST $56.10
- NUVL $77.93
- Average True Range (ATR)
- UPST 3.06
- NUVL 3.15
- MACD
- UPST 0.11
- NUVL -0.43
- Stochastic Oscillator
- UPST 21.48
- NUVL 4.63
About UPST Upstart Holdings Inc.
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit, and small-dollar loans.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.